默沙东/科伦博泰 TROP2 ADC 又双叒叕启动 III 期临床试验

Insight数据库
14 May

5 月 13 日,ClinicalTrials 网站显示,默沙东登记了一项比较 Sac-TMT(芦康沙妥珠单抗,TROP2 ADC)联合帕博利珠单抗和卡铂/紫杉醇对比化疗联合帕博利珠单抗新辅助治疗高危、早期三阴性乳腺癌或激素受体低阳性/人表皮生长因子受体 2 阴性乳腺癌的 III 期临床研究(NCT06966700/MK-2870-032)。截图来源:ClinicalTrials 网站这是一项...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10